
pages_aktie_[isin]_directordealings_0
components_InsiderTable_9
Frontier IP Group
pages_aktie_[isin]_directordealings_2
pages_insiderkaeufe_[isin]__0 pages_insiderkaeufe_[isin]__1pages_insiderkaeufe_[isin]__2 pages_insiderkaeufe_[isin]__3pages_insiderkaeufe_[isin]__4 pages_insiderkaeufe_[isin]__5pages_aktie_[isin]_directordealings_3
The Frontier IP Group PLC is a British company specializing in technology investment and listed on the London Stock Exchange. The company was founded in 2000 and is headquartered in London. Frontier IP invests in promising technology companies and supports them in the development of their products. The business model of Frontier IP is based on investing in promising companies to further develop their technology and business areas. The company has extensive experience in technology development and marketing and works closely with its portfolio companies. Currently, Frontier IP is investing in numerous companies in various sectors such as biotechnology, artificial intelligence, environmental technology, and agricultural technology. The investments range from start-up companies to established companies already present in the market. Each company in which Frontier IP is involved has unique technologies and innovations in the field of research and development, which have a significant impact on their respective markets. The products and services offered by Frontier IP and its portfolio companies include various biotechnological products and procedures, including antibodies, vaccines, and cell therapies. Frontier IP also invests in companies that develop advanced sensor technologies, robotics, and AI systems that can contribute to the automation of various industries. One example is The Vaccine Group. The Vaccine Group was founded in 2003 as a spin-off from the University of Plymouth and is a leading developer of novel human vaccines. The focus is on developing vaccines against infectious diseases classified as special challenges by the World Health Organization (WHO). Another example is Exscientia. Exscientia specializes in applied AI technology to accelerate drug discovery and development. The company has already achieved several groundbreaking successes and collaborates with leading pharmaceutical companies to develop innovative formulations with shorter development times. Frontier IP has also invested in Cambridge Raman Imaging Limited, which has developed an innovative method for high-speed imaging of cells and biological samples. This technology can be used in medical diagnostics or in the development of new drugs. Overall, Frontier IP Group is a significant company in the technology and investment industry. The company specializes in investing in promising technology companies and has extensive expertise in technology development and marketing. Through its investments, Frontier IP has already developed innovative products and services that have a significant impact on various industries and markets and will continue to play an important role in the future.
components_InsiderFAQ__11
components_InsiderFAQ__0
components_InsiderFAQ__2
components_InsiderFAQ__4
components_InsiderFAQ__5
components_InsiderFAQ__7
components_InsiderFAQ__9
components_InsiderArticle__0
components_InsiderArticle__1
components_InsiderArticle__5
components_InsiderArticle__8
components_InsiderArticle__9
components_InsiderArticle__12
components_InsiderArticle__13
components_InsiderArticle__16
components_InsiderArticle__17
components_InsiderArticle__20
components_InsiderArticle__22
components_InsiderArticle__25
components_InsiderArticle__28
components_InsiderArticle__31
components_InsiderArticle__32
components_InsiderArticle__34
components_InsiderArticle__36
components_InsiderArticle__37
components_InsiderArticle__38
components_InsiderArticle__40
components_InsiderArticle__41 components_InsiderArticle__42 components_InsiderArticle__43 components_InsiderArticle__44 components_InsiderArticle__45
- components_InsiderArticle__48
- components_InsiderArticle__49
components_InsiderArticle__50
components_InsiderArticle__51
components_InsiderArticle__54
components_InsiderArticle__55
components_InsiderArticle__58
components_InsiderArticle__59
- components_InsiderArticle__61
- components_InsiderArticle__62
- components_InsiderArticle__63
- components_InsiderArticle__64
- components_InsiderArticle__65
- components_InsiderArticle__66
components_InsiderArticle__67
components_InsiderArticle__68
components_InsiderArticle__73
components_InsiderArticle__74
components_InsiderArticle__77
components_InsiderArticle__78
components_InsiderArticle__81
components_InsiderArticle__82
components_InsiderArticle__85
components_InsiderArticle__86 components_InsiderArticle__87. components_InsiderArticle__88
components_InsiderArticle__90
components_InsiderArticle__93
components_InsiderArticle__94
components_InsiderArticle__97
components_InsiderArticle__98
components_InsiderArticle__103
components_InsiderArticle__110
components_InsiderArticle__113
components_InsiderArticle__114
components_InsiderArticle__116
components_InsiderArticle__118 components_InsiderArticle__119 components_InsiderArticle__120
components_InsiderArticle__121
components_InsiderArticle__122
components_InsiderArticle__125
components_InsiderArticle__126
components_InsiderArticle__129
components_InsiderArticle__132
components_InsiderArticle__137
components_InsiderArticle__142
components_InsiderArticle__145
components_InsiderArticle__147
components_InsiderArticle__148
components_InsiderArticle__150
components_InsiderArticle__155
components_InsiderArticle__158
components_InsiderArticle__159
components_InsiderArticle__162
components_InsiderArticle__163
components_InsiderArticle__166
components_InsiderArticle__167
components_InsiderArticle__172
components_InsiderArticle__175
components_InsiderArticle__178
components_InsiderArticle__181
components_InsiderArticle__182
components_InsiderArticle__184
components_InsiderArticle__187
components_InsiderArticle__190
components_InsiderArticle__192
components_DirectorsDealingsText_5
components_InsiderArticle__196
components_InsiderArticle__197
components_InsiderArticle__199
components_InsiderArticle__200
components_InsiderArticle__203
components_InsiderArticle__206
components_InsiderArticle__209
components_InsiderArticle__212
components_InsiderArticle__215 components_DirectorsDealingsText_7 components_InsiderArticle__216 components_InsiderArticle__217